Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-()-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-()-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.


Pharmaceutical Technology



Figure 1
The racemic compound (R,S)-()-ibuprofen or (R, S)-()-2-(4-isobutylphenyl) propionic acid is a popular active pharmaceutical ingredient (API) in analgesic, anti-inflammatory, and antipyretic therapies (1) with abundant information about the compound provided in the literature (2–11). Ibuprofen is marketed as a racemate. The enantiomer (S)-(+)-ibuprofen is the active agent and the other enantiomer, (R)-(–)-ibuprofen, is partially converted into (S)-(+)-ibuprofen in humans. (R,S)-()-ibuprofen has several disadvantageous formulation properties such as poor water solubility of less than 1 mg/mL at 25 C, a low melting point of 77 C, and possible esterification with excipients containing a hydroxyl group (1). These problems can be easily overcome by using an (R,S)-()-ibuprofen salt such as the racemic compound (R,S)-()-sodium 2-(4-isobutyl–phenyl) propionate dihydrate or (R, S)-()-sodium ibuprofen dihydrate (see Figure 1), whose potential values over (R,S)-()-ibuprofen make the study of its solubility, polymorphism, crystallinity, crystal habit, and drying scheme meaningful (12).

In this study, the solubility of (R, S)-()-sodium ibuprofen dihydrate solids at 25 C was determined in 23 solvents using a robust and scalable initial solvent-screening method (13). Good solvents were identified, and the solubility curves of the solids in various good solvents were constructed. Good solvents were defined as solvents in which the solubility of racemic (R, S)-()-sodium ibuprofen dihydrate had a solubility of < 1 mg/mL at 25 C. All solids were produced from the supersaturated solution of the good solvents by temperature cooling from 60–25 C.

Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and powder X-ray diffraction (PXRD) determined the polymorphism, crystallinity, and drying scheme of the solid samples (14). Optical microscopy (OM) and scanning electron microscopy (SEM) were used for crystal-habit imaging. The solids' solubilities and crystal habits were related to the solvent microscopic properties of dispersion forces (δd) polar forces (δp), and hydrogen bonding (δh) by the Hansen model adopted from the paint industry at 25 C (15).

Solvent liquids generally are held together by van der Waals forces, which are electromagnetic interactions among molecules. The strength of van der Waals forces is directly reflected by the heat of vaporization (ΔHv). ΔHv can be translated into a correlation between vaporization and the solubility behavior because the types of intermolecular attractive forces needed to be overcome to vaporize a solvent liquid are the same as those that must be overcome to dissolve it. The Hildebrand numerical value (δt[Pa1/2 ]) of the solvency behavior of a specific solvent was invented as a function of ΔHv (15) in the following:











in which R is the gas constant (8.314 J/mol • K), T is the temperature (measured in K), and Vm is the molar volume (measured in m3 /mol).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here